touchCONGRESS The personalized patient experience in nAMD: What do the latest data tell us about optimizing clinical management?
Stay abreast of the latest research on the clinical management of neovascular age-related macular degeneration (nAMD) for individual patients by watching a webinar and interviews with international experts reviewing data from the virtual proceedings of the World Ophthalmology Congress 2020 (WOC2020 Virtual).
Part 1: Watch internationally renowned expert Prof. Pravin Dugel review key data from WOC2020 Virtual
Part 2: Choose from leading experts who discuss what the data findings mean for global and regional practice
Introduction: WOC2020 Virtual®
Symposia highlights: Novel therapies and retinal fluid management
Symposia highlights: Home monitoring and novel delivery systems
Congress abstracts on novel treatments for nAMD
Overview
Watch Pravin Dugal review key data and congress highlights from WOC2020 Virtual and consider:
- How does the latest evidence inform the management of retinal fluid in nAMD?
- What do assessments of anti-VEGF therapies tell us about optimal dosing schedules in nAMD?
- Can novel therapies and drug delivery systems reduce treatment burden in nAMD?
- Is there a central role for home monitoring in nAMD?
About Prof. Pravin Dugel
Prof. Pravin Dugel is Clinical Professor at the USC Roski Eye Institute, Keck School of Medicine, University of Southern California, USA.
Prof. Dugel is internationally recognized as a major clinical researcher and has been a primary investigator in over 100 multicentre clinical trials. His research and educational contributions have earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO).
Prof. Pravin Dugel discloses: Advisory boards for Acucela, Aerpio, Alcon Pharmaceutical, Alcon Surgical (RACII), Alimera Sciences, Abbott Medical Optics Incs, Annidis, ArticDX, ASRS Board, Avalanche, Bausch, Beyeonics, CDR-Life Inc., Clearside Biomedical, Digisight, DOSE Medical, Euretina Board, Gemini Pharmaceutical, Genentech, Graybug Vision, Lutronic, LUX BioScience, MacuSight, NeoVista, Neurotech, Novartis, Oculis, Omeros, Opthea, Ophthotech, Orbis International, Oxurion, Regenxbio, Reneuron, Retina World Congress, Roche, Santen, Inc, Shire Human Genetics, Stealth Biotherapeutics, Thrombogenics and TrueVision. Consultant for Acucela, Aerie Pharmaceutical, Aerpio, Alcon Pharmaceutical, Alcon Surgical, Allergan, Alimera Sciences, Amgen, Annidis, ArticDX, Arctic Vision, AsclepiX Therapeutics Inc., Bausch & Lomb Pharma, BeyeOnics, BioBridge/Retinagenix, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Daiichi Sankyo, DigiSight, DOSE Medical, FoxKiser, Gemini Pharmaceutical, Genentech, Glaukos, Graybug Vision, Kodiak Sciences, Irenix, jCyte, Ionis, Lutronic, LUX BioScience, MacuSight, Merck, Nan Fung Group, NeoVista, Neurotech, Novartis, Oculis SA, Omeros, Opthea, Ophthotech, Optovue, ORA, PanOptica, Pentavision, Pieris Pharmaceutical, pSiveda/Eyepoint, RegenexBio, Reneuron. Roche, Santen, Inc., SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenics, TopCon and Zeiss Group. Minor stockholder with Aerpio, Allegro, ArctixDx, Arctic Vision, Clearside Biomedical, Digisight/Verana, FoxKiser, Graybug, Irenix, Nan Fung Group, Oculis, Ophthotech, PanOptica, SciFluor and TrueVision. Employee and shareholder at IVERIC Bio.
Prof. Frank G Holz, Professor and Chair of the Department of Ophthalmology at the University of Bonn, Germany, provides his expert insights into the key data from WOC2020 Virtual on the management of nAMD in a post-COVID-19 era.
Interview Questions
In this interview, Frank G Holz answers the following questions:
- How might treatment schedules for approved anti-VEGF agents be adapted due to the ongoing COVID-19 pandemic?
- How will the ongoing COVID-19 pandemic affect the uptake of recently approved novel anti-VEGF agents and technologies for the treatment of nAMD?
- Compared with the period before the COVID-19 pandemic, do you intend to change your approach to the treatment of nAMD?
- How will the ongoing COVID-19 pandemic affect the assessment and monitoring of patients with nAMD, including the use of home monitoring?
About Prof. Frank G Holz
Prof. Frank G Holz is Professor and Chairman of the Department of Ophthalmology at the University of Bonn, Germany. Prof. Holz’s major clinical interest is surgical and medical retina. His scientific interests include pathogenesis, prognostic factors, biomarkers and treatment of macular and retinal diseases, and innovative retinal imaging technologies. He trained at the University of Chicago Pritzker School of Medicine, IL, USA, and completed a fellowship at Moorfields Eye Hospital, London, UK with Prof. Alan C Bird.
Prof. Holz was a co-founder of the German Research Foundation Priority Program for AMD (DFG) and the GRADE Reading Center in Bonn. He is project lead of the MACUSTAR study funded by the European Union Innovative Medicines Initiative 2 (IMI2 EU) programme.
He is a board member of the German Ophthalmological Society and EURETINA; a member of the European Academy of Ophthalmology, the Macula Society, the Club Jules Gonin, and the Gass Club; Editor-in-Chief of Der Ophthalmologe; and serves as a reviewer for many peer-reviewed journals.
Prof.Holz has received numerous awards, including the Leonhard Klein Award for Ocular Surgery, the Alcon Research Institute Award, the Senior Achievement Award from the AAO, and the Jules Gonin Award.
Prof. Frank G Holz discloses: Consultancy for Acucela, Alcon/Novartis, Allergan, Bayer, Boehringer-Ingelheim, Genentech/Roche, LIN Bioscience and Pixium. Research grants from Allergan, Bayer, Carl Zeiss Meditec, Nightstar Therapeutics, Optos, Roche/Genentech and Pixium. Speaker honoraria from Alcon/Novartis, Bayer, Heidelberg Engineering. Roche/Genentech and Zeiss.
Prof. Pravin Dugel, a leading retinal specialist from Phoenix, AZ, USA, provides his expert insights into the key data from WOC2020 Virtual on the management of nAMD in a post-COVID-19 era.
Interview Questions
In this interview, Pravin Dugal answers the following questions:
- How might treatment schedules for approved anti-VEGF agents be adapted due to the ongoing COVID-19 pandemic?
- How will the ongoing COVID-19 pandemic affect the uptake of recently approved novel anti-VEGF agents and technologies for the treatment of nAMD?
- Compared with the period before the COVID-19 pandemic, do you intend to change your approach to the treatment of nAMD?
- How will the ongoing COVID-19 pandemic affect the assessment and monitoring of patients with nAMD, including the use of home monitoring?
About Prof. Pravin Dugel
Prof. Pravin Dugel is Clinical Professor at the USC Roski Eye Institute, Keck School of Medicine, University of Southern California, USA.
Prof. Dugel is internationally recognized as a major clinical researcher and has been a primary investigator in over 100 multicentre clinical trials. His research and educational contributions have earned him the prestigious Senior Honor Award from the American Academy of Ophthalmology (AAO).
Prof. Pravin Dugal discloses: Advisory boards for Acucela, Aerpio, Alcon Pharmaceutical, Alcon Surgical (RACII), Alimera Sciences, Abbott Medical Optics Incs, Annidis, ArticDX, ASRS Board, Avalanche, Bausch, Beyeonics, CDR-Life Inc., Clearside Biomedical, Digisight, DOSE Medical, Euretina Board, Gemini Pharmaceutical, Genentech, Graybug Vision, Lutronic, LUX BioScience, MacuSight, NeoVista, Neurotech, Novartis, Oculis, Omeros, Opthea, Ophthotech, Orbis International, Oxurion, Regenxbio, Reneuron, Retina World Congress, Roche, Santen, Inc, Shire Human Genetics, Stealth Biotherapeutics, Thrombogenics and TrueVision. Consultant for Acucela, Aerie Pharmaceutical, Aerpio, Alcon Pharmaceutical, Alcon Surgical, Allergan, Alimera Sciences, Amgen, Annidis, ArticDX, Arctic Vision, AsclepiX Therapeutics Inc., Bausch & Lomb Pharma, BeyeOnics, BioBridge/Retinagenix, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Daiichi Sankyo, DigiSight, DOSE Medical, FoxKiser, Gemini Pharmaceutical, Genentech, Glaukos, Graybug Vision, Kodiak Sciences, Irenix, jCyte, Ionis, Lutronic, LUX BioScience, MacuSight, Merck, Nan Fung Group, NeoVista, Neurotech, Novartis, Oculis SA, Omeros, Opthea, Ophthotech, Optovue, ORA, PanOptica, Pentavision, Pieris Pharmaceutical, pSiveda/Eyepoint, RegenexBio, Reneuron. Roche, Santen, Inc., SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenics, TopCon and Zeiss Group. Minor stockholder with Aerpio, Allegro, ArctixDx, Arctic Vision, Clearside Biomedical, Digisight/Verana, FoxKiser, Graybug, Irenix, Nan Fung Group, Oculis, Ophthotech, PanOptica, SciFluor and TrueVision. Employee and shareholder at IVERIC Bio.
Dr Kelvin Teo from the Medical Retina Department, Singapore National Eye Centre, Singapore, provides his expert insights into the key data from WOC2020 Virtual on the management of nAMD in a post-COVID-19 era.
Interview Questions
In this interview, Kelvin Teo answers the following questions:
- How might treatment schedules for approved anti-VEGF agents be adapted due to the ongoing COVID-19 pandemic?
- How will the ongoing COVID-19 pandemic affect the uptake of recently approved novel anti-VEGF agents and technologies for the treatment of nAMD?
- Compared with the period before the COVID-19 pandemic, do you intend to change your approach to the treatment of nAMD?
- Compared with the period before the COVID-19 pandemic, do you intend to change your approach to the treatment of nAMD?
About Dr Kelvin Teo
Dr Kelvin Teo is a consultant ophthalmologist in the Medical Retina Department at the Singapore National Eye Centre. He has a strong interest in clinical research in the field of medical retina. In particular, his focus is on real-world outcomes and how imaging techniques help to advance the pathophysiology and therapy of nAMD.
Dr Kelvin Teo discloses no financial interests/relationships or affiliations in relation to this activity.
Please Select A Video:
Overview & Learning Objectives
Overview
In this activity, internationally recognized experts in ophthalmology discuss the latest data on the clinical management of nAMD, including the importance of regular monitoring, application of optimal dosing regimens for individual patients and role of novel drug delivery systems and agents.
This activity has been jointly provided by Oakstone and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians.
Target Audience
This activity is designed to meet the educational needs of ophthalmologists and retinal disease specialists worldwide.
Disclosures
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest were resolved for fair balance and scientific objectivity of studies utilized in this activity. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relevant commercial interests.
Faculty
Prof. Pravin Dugal Discloses: Advisory board member: Acucela, Aerpio, Alcon Pharmaceutical, Alcon Surgical (RACII), Alimera Sciences, Abbott Medical Optics Incs, Annidis, ArticDX, ASRS Board, Avalanche, Bausch, Beyeonics, CDR-Life Inc., Clearside Biomedical, Digisight, DOSE Medical, Euretina Board, Gemini Pharmaceutical, Genentech, Graybug Vision, Lutronic, LUX BioScience, MacuSight, NeoVista, Neurotech, Novartis, Oculis, Omeros, Opthea, Ophthotech, Orbis International, Oxurion, Regenxbio, Reneuron, Retina World Congress, Roche, Santen, Inc, Shire Human Genetics, Stealth Biotherapeutics, Thrombogenics and TrueVision; Consultant for, Acucela, Aerie Pharmaceutical, Aerpio, Alcon Pharmaceutical, Alcon Surgical, Allergan, Alimera Sciences, Amgen, Annidis, ArticDX, Arctic Vision, AsclepiX Therapeutics Inc., Bausch & Lomb Pharma, BeyeOnics, BioBridge/Retinagenix, Boehringer Ingelheim, Chengdu Kanghong Biotechnology, Clearside Biomedical, Daiichi Sankyo, DigiSight, DOSE Medical, FoxKiser, Gemini Pharmaceutical, Genentech, Glaukos, Graybug Vision, Kodiak Sciences, Irenix, jCyte, Ionis, Lutronic, LUX BioScience, MacuSight, Merck, Nan Fung Group, NeoVista, Neurotech, Novartis, Oculis SA, Omeros, Opthea, Ophthotech, Optovue, ORA, PanOptica, Pentavision, Pieris Pharmaceutical, pSiveda/Eyepoint, RegenexBio, Reneuron. Roche, Santen, Inc., SciFluor Life Sciences, Shire Human Genetics, Spark Therapeutics, Stealth Biotherapeutics, Thrombogenics, TopCon and Zeiss Group; Minor stockholder with: Aerpio, Allegro, ArctixDx, Arctic Vision, Clearside Biomedical, Digisight/Verana, FoxKiser, Graybug, Irenix, Nan Fung Group, Oculis, Ophthotech, PanOptica, SciFluor and TrueVision. Employee and shareholder: IVERIC Bio.
Content Reviewer
Walter Murray Yarbrough, MD, FACP, has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Kathy Day has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu)
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 22 July 2020. Date credits expire: 22 July 2021.
Learning Objectives
After watching this touchCONGRESS, you should be able to:
- Evaluate strategies for the management of retinal fluid in nAMD
- Interpret results from clinical trials and real-world experience to inform on optimal dosing of anti-VEGF in nAMD
- Recall factors that contribute to optimization of clinical management and reduction in treatment burden for patients with nAMD